Ginkgo Bioworks Holdings (DNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ginkgo Bioworks Holdings (DNA) has a cash flow conversion efficiency ratio of -0.105x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.43 Million) by net assets ($443.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Ginkgo Bioworks Holdings to measure how much of total assets are equity-financed.
Ginkgo Bioworks Holdings - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Ginkgo Bioworks Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how much of Ginkgo Bioworks Holdings's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Ginkgo Bioworks Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ginkgo Bioworks Holdings ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stitch Fix
NASDAQ:SFIX
|
0.058x |
|
Hangzhou Landscaping Incorporated
SHG:605303
|
0.090x |
|
Hangzhou Century Co Ltd
SHE:300078
|
0.019x |
|
GREENLIGHT CAP.RE A DL-01
F:G8L
|
0.050x |
|
Jiangsu Changqing Agrochemical Co Ltd
SHE:002391
|
0.055x |
|
Nagarro SE
XETRA:NA9
|
0.166x |
|
Smartgen (Zhengzhou) Technology Co. Ltd. A
SHE:301361
|
N/A |
|
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
|
-0.065x |
Annual Cash Flow Conversion Efficiency for Ginkgo Bioworks Holdings (2019–2025)
The table below shows the annual cash flow conversion efficiency of Ginkgo Bioworks Holdings from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Ginkgo Bioworks Holdings (DNA) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $508.59 Million | $-171.06 Million | -0.336x | +24.64% |
| 2024-12-31 | $716.06 Million | $-319.58 Million | -0.446x | -65.71% |
| 2023-12-31 | $1.10 Billion | $-295.50 Million | -0.269x | -85.42% |
| 2022-12-31 | $1.74 Billion | $-252.20 Million | -0.145x | +10.30% |
| 2021-12-31 | $1.57 Billion | $-253.82 Million | -0.162x | +43.96% |
| 2020-12-31 | $470.05 Million | $-135.83 Million | -0.289x | -224.70% |
| 2019-12-31 | $501.85 Million | $-44.66 Million | -0.089x | -- |
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artific… Read more